Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070756 | 1.00 | NPSR1 (0.38) | NPSR1KDM4EMEN1KMT2ADHODH | |
| SCHEMBL2070675 | 0.75 | GABRG2 (0.46) | MEN1KMT2ASMN1; SMN2POLBTP53 | |
| SCHEMBL2071032 | 0.74 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL2069197 | 0.69 | KDM4E (0.47) | NPSR1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4656876 | 0.69 | POLB (0.43) | KDM4EMEN1KMT2ASMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL2070338 | 0.68 | HCAR1 (0.44) | NPSR1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2071880 | 0.60 | CYP11B2 (0.46) | NPSR1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2069678 | 0.59 | HCAR1 (0.36) | KDM4EMEN1KMT2APOLBTP53 | |
| SCHEMBL1052996 | 0.59 | NPSR1 (0.33) | NPSR1KDM4EMEN1KMT2ADHODH | |
| SCHEMBL10861478 | 0.59 | MEN1 (0.79) | NPSR1KDM4EMEN1KMT2ADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| EP-1732541-A4 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| EP-1732541-A2 | CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005099688-A2 | CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | NPSR1 37/4885KDM4E 3537/4885MEN1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.